Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
OVERTURE
Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
1 other identifier
interventional
30
1 country
5
Brief Summary
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_1
Started May 2026
Typical duration for phase_1
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 8, 2026
CompletedFirst Posted
Study publicly available on registry
May 14, 2026
CompletedStudy Start
First participant enrolled
May 19, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2028
May 22, 2026
May 1, 2026
2 years
May 8, 2026
May 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Incidence and severity of ocular treatment-emergent adverse events (TEAEs)
Week 72
Incidence and severity of systemic treatment-emergent adverse events (TEAEs)
Week 72
Study Arms (4)
EYC-0305 Dose Level 1
EXPERIMENTALEYC-0305 Dose Level 2
EXPERIMENTALEYC-0305 Dose Level 3
EXPERIMENTALEYC-0305 Dose Level 4
EXPERIMENTALInterventions
Extended-delivery anti-VEGF
Eligibility Criteria
You may qualify if:
- Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
- Willing and able to comply with clinic visits and study-related procedures
- Provide signed informed consent
You may not qualify if:
- Known hypersensitivity or known allergy that would preclude study drug administration
- Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
- Uncontrolled diabetes mellitus
- History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
- Renal failure, dialysis, or history of renal transplant
- Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion
- Pregnant or breastfeeding women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Eyconis INC.lead
Study Sites (5)
Beverly Hills, CA
Beverly Hills, California, 90211, United States
Erie, PA
Erie, Pennsylvania, 16505, United States
Bellaire, TX
Bellaire, Texas, 77401, United States
McAllen, TX
McAllen, Texas, 78503, United States
The Woodlands, TX
The Woodlands, Texas, 77384, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 8, 2026
First Posted
May 14, 2026
Study Start
May 19, 2026
Primary Completion (Estimated)
May 1, 2028
Study Completion (Estimated)
May 1, 2028
Last Updated
May 22, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Following publication of the final study results.
- Access Criteria
- IPD will be shared with researchers who provide a methodologically sound proposal.
IPD reported in results publication will be shared